急诊剖腹术术前大剂量地塞米松随机临床试验
这项双盲安慰剂对照试验将120例急诊剖腹术患者按肠梗阻和空腔脏器穿孔分层,随机给予术前1 mg/kg地塞米松或安慰剂。地塞米松组术后第1天C反应蛋白显著降低,且恢复指标改善、90天死亡率(7%对23%)和术后重大并发症发生率(27%对45%)均降低。
要点
- 术前单次1 mg/kg地塞米松可显著降低急诊剖腹术后的炎症反应。
- 地塞米松组恢复更快,包括血流动力学、肺功能、疲劳和早期活动改善。
- 地塞米松组90天死亡率和术后重大并发症发生率均低于安慰剂组。
核心结论
- 术前单次大剂量静脉地塞米松可显著降低急诊剖腹术后的炎症反应,并与恢复增强和结局改善相关。
研究设计与样本
- 双盲安慰剂对照试验,患者按手术病理(肠梗阻和空腔脏器穿孔)前瞻性分层,按1:1随机分配至术前1 mg/kg地塞米松或安慰剂组,共纳入120例患者。
主要发现
- 术后第1天C反应蛋白中位数地塞米松组为170 mg/l,安慰剂组为220 mg/l(P=0.015;平均差49 mg/l,95%CI 13至85)。
- 肠梗阻亚组术后第1天C反应蛋白中位数地塞米松组为60 mg/l,安慰剂组为160 mg/l(P=0.002)。
- 空腔脏器穿孔亚组术后第1天C反应蛋白中位数地塞米松组为230 mg/l,安慰剂组为285 mg/l(P=0.035)。
- 地塞米松组90天死亡率为7%,安慰剂组为23%(相对风险0.33,95%CI 0.11至0.93;P=0.023)。
- 地塞米松组术后重大并发症发生率为27%,安慰剂组为45%(相对风险0.62,95%CI 0.37至1.00;P=0.032)。
临床怎么用
- 对急诊剖腹术患者,可考虑术前单次静脉给予1 mg/kg地塞米松以减轻炎症反应并改善恢复。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients undergoing emergency laparotomy present with a profound inflammatory response, which could be an independent pathophysiological component in prolonged recovery. The aim of this study was to investigate the effects of a single preoperative high dose of intravenous dexamethasone on the inflammatory response and recovery after emergency laparotomy. METHODS: In this double-blinded placebo-controlled trial, patients were prospectively stratified according to surgical pathology (intestinal obstruction and perforated viscus) and randomized to preoperative 1 mg/kg dexamethasone or placebo at a ratio of 1 : 1. The primary outcome was C-reactive protein on postoperative day 1. Secondary outcomes were postoperative recovery, morbidity, and mortality. RESULTS: A total of 120 patients were included in the trial. On postoperative day 1, the C-reactive protein response was significantly lower in the dexamethasone group (a median of 170 versus 220 mg/l for dexamethasone and for placebo respectively; P = 0.015; mean difference = 49 (95% c.i. 13 to 85) mg/l) and when stratified according to intestinal obstruction (a median of 60 versus 160 mg/l for dexamethasone and for placebo respectively; P = 0.002) and perforated viscus (a median of 230 versus 285 mg/l for dexamethasone and for placebo respectively; P = 0.035). Dexamethasone administration was associated with improved recovery (better haemodynamics, better pulmonary function, less fatigue, and earlier mobilization). Furthermore, the dexamethasone group had a lower 90-day mortality rate (7% versus 23% for dexamethasone and for placebo respectively; relative risk 0.33 (95% c.i. 0.11 to 0.93); P = 0.023) and a decreased incidence of postoperative major complications (27% versus 45% for dexamethasone and for placebo respectively; relative risk 0.62 (95% c.i. 0.37 to 1.00); P = 0.032). CONCLUSION: A single preoperative high dose of intravenous dexamethasone significantly reduces the inflammatory response after emergency laparotomy and is associated with enhanced recovery and improved outcome. REGISTRATION NUMBER: NCT04791566 (http://www.clinicaltrials.gov).
引用
- Cihoric M, Kehlet H, Lauritsen ML, et al. Preoperative high dose of dexamethasone in emergency laparotomy: randomized clinical trial. Br J Surg. 2024. PMID: 39028763. doi:10.1093/bjs/znae130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。